openheart 180-day readmission risk model for older adults with acute myocardial infarction: the SILVER-AMI study

John A Dodson ^{1,2}, Alexandra M Hajduk,³ Terrence E Murphy,³ Mary Geda,³ Harlan M Krumholz,^{4,5,6,7} Sui Tsang,³ Michael G Nanna,⁸ Mary E Tinetti,³ Gregory Ouellet,³ Deborah Sybrant,⁹ Thomas M Gill,³ Sarwat I Chaudhry¹⁰

► Additional material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/openhrt-2020-001442>).

To cite: Dodson JA, Hajduk AM, Murphy TE, *et al.* 180-day readmission risk model for older adults with acute myocardial infarction: the SILVER-AMI study. *Open Heart* 2021;**8**:e001442. doi:10.1136/openhrt-2020-001442

Received 8 September 2020
Revised 11 November 2020
Accepted 13 December 2020

ABSTRACT

Objective To develop a 180-day readmission risk model for older adults with acute myocardial infarction (AMI) that considered a broad range of clinical, demographic and age-related functional domains.

Methods We used data from Comprehensive Evaluation of Risk in Older Adults with AMI (SILVER-AMI), a prospective cohort study that enrolled participants aged ≥75 years with AMI from 94 US hospitals. Participants underwent an in-hospital assessment of functional impairments, including cognition, vision, hearing and mobility. Clinical variables previously shown to be associated with readmission risk were also evaluated. The outcome was 180-day readmission. From an initial list of 72 variables, we used backward selection and Bayesian model averaging to derive a risk model (N=2004) that was subsequently internally validated (N=1002).

Results Of the 3006 SILVER-AMI participants discharged alive, mean age was 81.5 years, 44.4% were women and 10.5% were non-white. Within 180 days, 1222 participants (40.7%) were readmitted. The final risk model included 10 variables: history of chronic obstructive pulmonary disease, history of heart failure, initial heart rate, first diastolic blood pressure, ischaemic ECG changes, initial haemoglobin, ejection fraction, length of stay, self-reported health status and functional mobility. Model discrimination was moderate (0.68 derivation cohort, 0.65 validation cohort), with good calibration. The predicted readmission rate (derivation cohort) was 23.0% in the lowest quintile and 65.4% in the highest quintile.

Conclusions Over 40% of participants in our sample experienced hospital readmission within 180 days of AMI. Our final readmission risk model included a broad range of characteristics, including functional mobility and self-reported health status, neither of which have been previously considered in 180-day risk models.

INTRODUCTION

Over the past decade, healthcare systems in the USA and Europe have put considerable resources into understanding and preventing 30-day readmissions among older adults.^{1,2} Financial concerns have driven much of these efforts: in the USA, hospitals face financial penalties for excessive 30-day readmission

Key questions

What is already known about this subject?

► For older adults, hospital readmission risk after acute myocardial infarction (AMI) extends beyond the 30-day window traditionally set by payors. Readmission at 180 days more fully encompasses the heightened state of vulnerability after discharge.

What does this study add?

► We considered a broad range of clinical characteristics and functional impairments among patients aged ≥75 years hospitalised with AMI, and 10 were retained in a risk model for readmission at 180 days. Two of these (functional mobility and self-reported health status) are not usually collected in routine care.

How might this impact on clinical practice?

► Our risk model can be used at the point of care to identify older adults at increased readmission risk within 180 days, although our model discrimination was only moderate, indicating that other factors also contribute to risk.

rates in several conditions including acute myocardial infarction (AMI).¹ While 30-day readmission events are important from a cost and patient perspective, the period of heightened vulnerability to adverse events (termed the ‘post hospital syndrome’)³ extends beyond this payor-set benchmark. For example, a prior study of Medicare beneficiaries hospitalised for AMI demonstrated that readmission risk remained elevated for several months following discharge.⁴ In light of this phenomenon, considering a longer time horizon of 180 days after discharge may better reflect the vulnerabilities faced by older adults after hospitalisation for AMI.

Despite their relevance for patients, caregivers and health systems, determinants of 180-day readmissions after AMI remain largely unknown. While age alone appears to confer readmission risk beyond 30 days,⁵

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr John A Dodson; John.Dodson@nyumc.org

impairments in functional domains that are increasingly prevalent with advanced age, including cognition, vision, hearing and muscle strength, may also heighten the likelihood of readmission through mechanisms such as increased difficulty comprehending care instructions, delayed recognition of symptoms and increased fall risk. While our own group,⁶ and other investigators,⁷ have demonstrated that these age-associated functional impairments influence 30-day readmission, they have not yet been evaluated in the setting of 180-day readmissions.

In this context, our aim was to develop and validate a 180-day readmission risk model that considered both traditional demographic and clinical variables as well as age-related functional impairments. We used data from the Comprehensive Evaluation of Risk in Older Adults with AMI (SILVER-AMI) study, a prospective multi-centre longitudinal study of patients age ≥ 75 years who were hospitalised with AMI. Participants enrolled in SILVER-AMI underwent a detailed assessment of age-related functional impairments at the time of hospitalisation. In parallel, detailed clinical information (including variables from prior AMI risk models) was collected. Results from this study can be used to inform prognosis and the design of interventions for older patients at highest risk of 180-day readmission.

METHODS

Study participants

The design of SILVER-AMI has been described previously.⁸ Briefly, patients age ≥ 75 years were enrolled if they met criteria for the Third Universal Definition of AMI,⁹ as verified by physician investigators at the Yale Coordinating Center. Patients underwent a baseline assessment (in-hospital), including demographics, prehospital symptoms, health status measures (SF-12, Seattle Angina Questionnaire) and a comprehensive functional assessment. Medical records were also provided to the Yale Coordinating Center, where two physicians reviewed AMI eligibility criteria and readmission events, and a research nurse obtained information about medications, cardiac procedures and other details of the hospitalisation. All SILVER-AMI enrolment sites obtained institutional review board approval, and all participants provided written informed consent. While patients were not involved in all stages of study planning, the design of SILVER-AMI was presented to Community Advisory Board directed by the Yale Program on Aging, which is comprised of 8–10 older adult volunteers residing in the New Haven area who meet quarterly to provide feedback about best practices for making the research relevant and impactful to the older adult community.

From 1 November 2013 to 28 October 2016, 3041 participants were enrolled at 94 US study sites/hospitals, with the last follow-up assessment completed on 14 June 2017. The majority of sites were non-academic hospitals (71%), and 53% were located in suburban or rural areas. For purposes of our study, which modelled readmission

risk at 180 days, we excluded participants who died in-hospital ($n=35$), leaving an analytic sample of 3006 participants. We randomly selected 2004 for the derivation cohort, and 1002 for the validation cohort. This allocation of the overall sample allowed sufficient power to derive and validate the risk prediction model.

Outcome

A primary outcome of the SILVER-AMI study was all-cause readmission within 180 days of hospital discharge, which included any overnight hospital stay. Readmissions were identified through a two-step process. During enrolment, the participant identified the hospitals they used for medical care and signed the appropriate medical release forms. When the 180-day follow-up window closed, the research coordinator contacted hospitals that were identified at enrolment to assess and collect readmission records. Separately, participants also reported hospital readmissions to the Yale Coordinating Center. The Yale Coordinating Center then reconciled the hospital records collected by the coordinator against self-reported events to ensure that no readmissions were missing. Readmissions (occurrence and causes) were double-adjudicated by physician investigators at the Yale Coordinating Center. For the purpose of this analysis, we included readmission as a dichotomous variable and did not include subsequent readmissions. Mortality was ascertained through medical record review as well as through interviews with family members, with verification by death certificates, hospital records or obituaries.

Selection of predictors

For development of our 180-day risk model, we initially selected 72 candidate variables (online supplemental appendix eTable 1) based on: (1) elements from existing AMI readmission risk models,^{10–13} (2) major functional impairments plausibly related to readmission, including cognitive, sensory and physical function and (3) other clinical variables that, per the clinical judgement of the study investigators, may potentially influence readmission (such as symptom burden, self-reported health status and in-hospital complications). The following functional domains were considered: general cognitive function (Telephone Interview for Cognitive Status),¹⁴ verbal fluency (Controlled Word Association Task),¹⁵ vision impairment (Visual Functioning Questionnaire),¹⁶ hearing impairment (global question about impairments imposed by hearing),¹⁷ poor nutrition (4.5 kg weight loss in prior year), activities of daily living disability,¹⁸ depressive symptoms (Patient Health Questionnaire 8),¹⁹ upper extremity strength (handheld dynamometer, B&L Engineering, Santa Ana, California, USA),²⁰ fall history and functional Timed Up and Go (TUG),²¹ which involved evaluation of chair rise and gait speed over a distance of 3 m (online supplemental appendix eTable 2). When possible, we selected cutpoints for all functional impairments based on previously validated thresholds^{14–17 19};

if there was ambiguity, a consensus was reached among study team members based on the best available evidence.

Statistical analysis

We generated descriptive statistics in the overall cohort, using means for continuous variables and percentages for categorical variables. For categorical variables, we chose thresholds based on clinical relevance and distributions. From our initial list, we omitted variables with >20% missingness and those with extremely low (<5%) or high (>95%) prevalence. Under the assumption that data were missing at random, we multiply imputed the data 20 times. Per recommendations of White *et al.*²² we reduced the number of candidate variables by applying multivariable logistic regression with backward selection to an aggregate dataset of the 20 imputations, retaining the 30 variables with the strongest adjusted associations with the outcome. We then applied Bayesian model averaging with multivariable logistic regression to these final candidates in each of the multiply imputed datasets.²³ The final predictors were those exhibiting a positive posterior probability in at least half of the imputations. These predictors were subsequently examined for linearity and used in a multivariable model fit to each imputation using generalised estimating equations to adjust for the clustering of patients within hospitals. The final coefficients were calculated using Rubin's rules.²⁴ Because Bayesian model averaging was used to select variables rather than the corresponding p values, some model terms may not exhibit p values below 0.05.²⁵ In order to compare the relative weight of predictors with different incremental change per unit (eg, linear vs categorical), we generated standardised beta coefficients whereby the mean of each variable equaled zero and the SD of each variable equaled 1.0.

Discrimination and calibration of the final model were respectively evaluated in both derivation and validation cohorts with the C-statistic and the Hosmer-Lemeshow goodness of fit statistic. Observed and predicted probabilities of the outcome were calculated for quintiles of the risk score obtained by applying the final model to the validation data.

Because of the potential for the competing risk of death to bias our study results, we performed sensitivity analyses to account for the 62 (3%) SILVER-AMI participants in the derivation cohort who died without being readmitted.²⁶ Specifically, we ran our analyses again after imputing the readmission outcome under the following three assumptions for these 62 individuals: (1) all were readmitted; (2) none were readmitted; and (3) readmitted based on missing at random. In order to evaluate robustness of our study results to the competing risk of death, we compared the CIs from these three assumptions with those from our primary analysis (which did not account for competing risk of death).

Analyses were performed in SAS V9.4, with the exception of the Bayesian model averaging, which used the R package named BMA. For bedside prognostication,

we then developed a web-based calculator derived from model effect estimates.

RESULTS

Baseline characteristics

The mean age of the study sample was 81.5 years; 44.4% of participants were women, and 10.5% were of non-white race. Slightly over one-quarter of the sample (26.3%) presented with ST elevation myocardial infarction. Over half (53.4%) had a known history of coronary artery disease, and 40.6% had undergone previous coronary revascularisation. Functional impairments were observed most commonly in mobility (TUG ≥ 15 s or unable to complete TUG) (71.2%), weak grip strength (60.1%), unintentional weight loss (21.9%) and multiple falls within the prior year (19.7%). The majority of participants (59.0%) experienced at least one in-hospital complication (which included bleeding, acute kidney injury, decompensated heart failure, arrhythmia or hyperglycaemic).

Readmission at 180 days

Within 180 days of discharge, 1222 unique participants (40.7% of study sample) experienced at least one hospital readmission. Overall, there were 2016 readmissions: 742 participants were readmitted once, 298 were readmitted twice and 182 were readmitted three or more times. The majority of readmissions (61.0%) were cardiac related (table 1). The most common cause of readmission was congestive heart failure (17.7%), followed by non-ST-elevated myocardial infarction (8.4%), elective procedure (7.0%) and arrhythmia (6.1%). There were 266 deaths (8.8% of study sample) within the same observation period.

In bivariate analyses, compared with participants who were not readmitted, those who were readmitted were of relatively similar age (81.7 vs 81.4 years, $p=0.097$) and sex (per cent male 53.8% vs 56.8%, $p=0.112$) but more likely to be non-white (12.0% vs 9.5%, $p=0.035$) and less likely to be married or living with a partner (47.2% vs 52.5%, $p=0.004$). Medical comorbidities were generally higher among readmitted participants (table 2). Participants who were readmitted also had more functional impairments including cognitive impairment (21.4% vs 16.5%, $p<0.001$), vision impairment (9.9% vs 7.6%, $p=0.024$), unintentional weight loss (25.0% vs 20.5%, $p=0.003$), multiple prior falls (23.6% vs 17.0%, $p<0.001$) and impaired functional mobility (78.5% vs 66.3%, $p<0.001$).

Multivariable results

After application of Bayesian model averaging to the derivation cohort, 10 variables were retained in the final prediction model: history of chronic obstructive pulmonary disease (COPD), history of heart failure, initial heart rate, first diastolic BP, ischaemic ECG changes, initial haemoglobin, ejection fraction, length of stay, self-reported health status and functional mobility (figure 1). The strongest predictors based on standardised beta

Table 1 Causes of 180-day hospital readmission

	Total (N=2016) (%)
Cardiovascular	1183 (58.7)
Congestive heart failure (CHF)	357 (17.7)
Non-ST-elevated myocardial infarction (NSTEMI)	169 (8.4)
Elective procedure	142 (7.0)
Arrhythmia	123 (6.1)
Non-cardiac chest pain	119 (5.9)
Unstable angina	103 (5.1)
Stroke	37 (1.8)
Other cardiovascular including hypertensive disease	26 (1.3)
Peripheral vascular disease, including aorta, carotids and extremities	25 (1.2)
Valvular heart disease	22 (1.1)
ST-elevated myocardial infarction (STEMI)	20 (1.0)
Thrombotic event	15 (0.7)
Cardiac syncope	13 (0.6)
Transient ischaemic attack	11 (0.6)
Non-cardiovascular	833 (41.3)
Bleeding episode	183 (9.1)
Other non-cardiovascular	168 (8.3)
Pneumonia including aspiration pneumonitis	68 (3.4)
Sepsis/septic shock	60 (3.0)
Fall/fracture	58 (2.9)
Renal disorders (renal failure, electrolyte and acid-base abnormalities)	45 (2.2)
COPD/asthma	41 (2.0)
Urinary tract infection and urinary system complaints	36 (1.8)
Skin and soft tissue infections	32 (1.6)
Pleural effusion/pneumothorax	24 (1.2)
Diabetes, including blood glucose abnormalities	19 (0.9)
Dehydration	19 (0.9)
Weakness/fatigue/failure to thrive	19 (0.9)
Syncope	17 (0.8)
Other lung disorders including acute, congenital and unspecified lung abnormalities	11 (0.6)
Vomiting	11 (0.6)
Clostridium difficile-associated infection	9 (0.5)
Primary cancer of trachea, bronchus, lung and pleura	8 (0.4)
Psychiatric	4 (0.2)
Fibrosis of lung and other chronic lung disorders	1 (0.1)

Table describes all readmissions among study sample; 1222 unique participants experienced readmission (742 readmitted once, 298 readmitted twice and 182 readmitted ≥ 3 times). COPD, chronic obstructive pulmonary disease.

coefficients were history of heart failure (OR 1.85, 95% CI 1.46 to 2.34; standardised beta=5.10), initial haemoglobin (OR 0.90 per g/dL unit increase, 95% CI 0.86 to 0.94, standardised beta=4.22) and self-reported health status (OR 1.17 per level worsening, 95% CI 1.07 to 1.29, standardised beta=3.30). Discrimination of this model

was moderate (C statistic 0.68 995% CI 0.675 to 0.685) derivation cohort, 0.65 (95% CI 0.638 to 0.654) validation cohort). The model demonstrated good calibration evidenced by p values >0.05 for the Hosmer-Lemeshow statistic across all multiply imputed datasets.

Figure 2 plots the means and CIs of the observed probabilities of readmission versus those predicted for the validation cohort for quintiles of the risk scores based on the coefficients of the model developed in the derivation cohort. The predicted readmission rate (derivation cohort) was 23.0% in the lowest quintile and 65.4% in the highest quintile of risk (full range of predicted risk: 14.3%–91.4%). The beta coefficients from the final regression equation are presented in online supplemental appendix eTable 3.

Sensitivity analyses

Under the assumptions that among participants who died before readmission, (1) all were readmitted, (2) none were readmitted or (3) readmitted based on missing at random, there were negligible changes in effect estimates. For example, for COPD, the OR assuming all were readmitted was 1.46 (95% CI 1.12 to 1.91); assuming none were readmitted, the OR was 1.54 (95% CI 1.16 to 2.04); and assuming readmission data were missing at random, the OR was 1.51 (95% CI 1.15 to 2.00). Full findings for these scenarios are shown in the online supplemental appendix eTable 4.

DISCUSSION

To our knowledge, we developed the first 180-day readmission risk model for older adults after hospitalisation for AMI. Our study had several important findings. First, over 40% of participants were readmitted at least once within 6 months; while heart failure was the most common cause, it accounted for fewer than one in five hospitalisations, underscoring the broad range of acute medical conditions (cardiac and non-cardiac) leading to readmissions. Second, participants who were readmitted had a greater burden of functional impairments, including cognitive impairment, vision impairment, unintentional weight loss, multiple prior falls and impaired functional mobility, although only functional mobility was retained in the final risk model. Third, our final risk model included a broad range of factors related to presentation characteristics (eg, ischaemic ECG changes and initial heart rate), medical history (prior heart failure and COPD), diagnostic testing (ejection fraction and haemoglobin), functional mobility and self-reported health status. Two of these factors (functional mobility and self-reported health status) are not typically collected in current practice but, among the 72 variables we considered, were among the final predictors.

We previously published a risk model for 30-day readmission in the same cohort, which was developed based on 547 participants readmitted within that timeframe.⁶ Our 30-day risk model had moderate discrimination (C

Table 2 Participant characteristics: readmitted versus not readmitted at 180 days (N=3006)

	180-day readmission (N=1222) Mean (SD) or N (%)	No 180-day readmission (N=1784) Mean (SD) or N (%)	P value
Demographics			
Age (years), mean (SD)	81.7 (5.06)	81.4 (4.98)	0.097
Male sex	658 (53.8)	1013 (56.8)	0.112
Non-white race	147 (12.0)	170 (9.5)	0.035
Married/living as married or with partner	577 (47.2)	937 (52.5)	0.004
Medical history			
Hypertension	1082 (88.5)	1484 (83.2)	<0.001
Dyslipidaemia	789 (64.6)	1109 (62.2)	0.180
Arrhythmia	370 (30.3)	379 (21.2)	<0.001
Heart failure	330 (27.0)	233 (13.1)	<0.001
Prior myocardial infarction	364 (29.8)	455 (25.5)	0.010
Prior revascularisation procedure	536 (43.9)	684 (38.3)	0.003
Peripheral arterial disease	181 (14.8)	182 (10.2)	<0.001
Valvular disease	194 (15.9)	155 (8.7)	<0.001
Stroke	234 (19.1)	234 (13.1)	<0.001
Diabetes mellitus	515 (42.1)	601 (33.7)	<0.001
COPD	221 (18.1)	205 (11.5)	<0.001
Current or ever smoker	693 (56.7)	973 (54.5)	0.217
Presentation characteristics			
STEMI	285 (23.3)	506 (28.4)	0.002
Chest pain as primary symptom	493 (40.3)	718 (40.2)	0.913
≥6 hours from symptoms to presentation	562 (46.0)	709 (39.7)	<0.001
Body mass index, mean (SD)	27.4 (5.36)	27.6 (5.31)	0.329
Killip Class II–IV	220 (18.0)	172 (9.6)	<0.001
First systolic BP, mm Hg, mean (SD)	142.4 (30.81)	148.3 (30.58)	<0.001
First diastolic BP, mm Hg, mean (SD)	76.2 (18.07)	79.3 (17.33)	<0.001
First heart rate, bpm, mean (SD)	85.7 (22.53)	82.1 (22.63)	<0.001
Initial haemoglobin, mean (SD)	12.4 (2.14)	13.1 (1.98)	<0.001
Initial WCC count, mean (SD)	10.1 (6.23)	9.3 (3.78)	<0.001
eGFR, mean (SD)	51.7 (20.65)	56.6 (19.23)	<0.001
TIMI score (NSTEMI), mean (SD)	4.7 (1.19)	4.6 (1.18)	0.058
TIMI score (STEMI), mean (SD)	6.5 (1.87)	5.9 (1.42)	<0.001
GRACE ACS score, mean (SD)	150.5 (23.21)	142.0 (21.39)	<0.001
In-hospital diagnostics, therapies and complications			
Left ventricular ejection fraction			<0.001
Normal (≥50%)	542 (44.4)	985 (55.2)	
Mildly reduced (40%–50%)	247 (20.2)	350 (19.6)	
Moderately reduced (30%–40%)	187 (15.3)	206 (11.5)	
Severely reduced (<30%)	116 (9.5)	96 (5.4)	
Medications within first 24 hours			
Aspirin	1160 (94.9)	1716 (96.2)	0.116
Antiplatelet agent (P2Y12 inhibitor)	719 (58.8)	1154 (64.7)	0.001
Beta blocker	945 (77.3)	1420 (79.6)	0.148
Intravenous antithrombotic agent			0.035
No agent	234 (19.1)	281 (15.8)	
Single agent (heparin or bivalirudin)	878 (71.8)	1320 (74.0)	

Continued

Table 2 Continued

	180-day readmission (N=1222) Mean (SD) or N (%)	No 180-day readmission (N=1784) Mean (SD) or N (%)	P value
Two agents (heparin or bivalirudin plus GP IIb/IIIa)	109 (8.9)	183 (10.3)	
Revascularisation status			<0.001
No cardiac catheterisation	229 (18.7)	229 (12.8)	
Cardiac catheterisation only	229 (18.7)	265 (14.9)	
Cardiac catheterisation with PCI	633 (51.8)	1067 (59.8)	
Coronary artery bypass graft surgery	131 (10.7)	223 (12.5)	
In-hospital complication: bleeding	337 (27.6)	436 (24.4)	0.053
In-hospital complication: acute kidney injury	349 (28.6)	343 (19.2)	<0.001
In-hospital complication: heart failure	219 (17.9)	195 (10.9)	<0.001
Functional impairments			
Cognitive impairment (TICS)			<0.001
No impairment (TICS ≥ 27)	961 (78.6)	1490 (83.5)	
Mild impairment (TICS 23–36)	147 (12.0)	167 (9.4)	
Moderate or severe impairment (TICS ≤ 22)	96 (7.9)	96 (5.4)	
Verbal fluency (total COWAT S words), mean (SD)	9.3 (4.74)	9.9 (4.78)	<0.001
Clinically significant vision impairment (VFQ-25)	121 (9.9)	135 (7.6)	0.024
Clinically significant hearing impairment	155 (12.7)	249 (14.0)	0.291
Unintentional weight loss (>10 lbs. in 1 year)	305 (25.0)	366 (20.5)	0.003
ADL disability (any)	198 (16.2)	214 (12.0)	0.001
Multiple falls (>1 within past year)	289 (23.6)	304 (17.0)	<0.001
Weak grip strength	781 (63.9)	1026 (57.5)	<0.001
Functional mobility (based on Timed Up and Go)			<0.001
Completed in ≤ 15 s	263 (21.5)	602 (33.7)	
Completed in >15 and ≤ 25 s	233 (19.1)	386 (21.6)	
Completed in >25 s	223 (18.2)	260 (14.6)	
Unable to complete	290 (23.7)	270 (15.1)	
Other measures			
Short-Form 12: general health question (four categories)			<0.001
Excellent or very good	286 (23.4)	556 (31.2)	
Good	414 (33.9)	692 (38.8)	
Fair	357 (29.2)	403 (22.6)	
Poor	161 (13.2)	131 (7.3)	
Depressive symptoms (PHQ-8 ≥ 10)	222 (18.2)	200 (11.2)	<0.001

For descriptive purposes, 'impaired functional mobility' defined as Timed Up and Go >15 s or unable to complete test.

Data missing for fewer than 5% of variables except for left ventricular ejection fraction (9.2%) and Timed Up and Go (15.9%).

ADL, activities of daily living; BP, blood pressure; COPD, chronic obstructive pulmonary disease; COPD, chronic obstructive pulmonary disease; COWAT, Controlled Oral Word Association Test; eGFR, estimated glomerular filtration rate; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; PHQ-8, Patient Health Questionnaire 8; STEMI, ST-elevation myocardial infarction; TICS, Telephone Interview for Cognitive Status; TIMI, thrombolysis in myocardial infarction; VFQ-25, Visual Function Questionnaire 25; WCC, white cell count.

statistic: 0.65 derivation cohort, 0.63 validation cohort), was well calibrated and included functional mobility, ejection fraction, COPD, arrhythmia, acute kidney injury, first diastolic blood pressure, P2Y12 inhibitor use and self-reported health status. In the current study, we focused on 180-day readmissions given that mechanistically, posthospital risk among older adults extends beyond the 30-day benchmark commonly set by payors. For example, Dhar-marajan *et al.*⁴ using a sample of over 500 000 Medicare

beneficiaries hospitalised with AMI, demonstrated that even 90 days after AMI, the risk for hospital admission was six times greater than among the general older adult population. These findings suggest there is a prolonged period of posthospital risk before restoration of homeostasis. Factors related to hospitalisation such as immobility, poor nutrition or iatrogenic events may contribute to these phenomena.^{3 27} Compared with our 30-day risk model, we found 180-day risk factors that were unique

Figure 1 Risk model elements: 180-day readmission. After Bayesian model averaging with multivariable logistic regression, 10 variables were retained in the final risk model: these included comorbidities, presentation characteristics, self-reported health status and functional mobility. *Based on Short-Form 12 general health: excellent or very good (reference), good, fair and poor. †ECG changes: no ischaemic changes (reference), ST depression or T-wave inversion, ST elevation. ‡Timed Up and Go scores: ≤15 s (reference), >15–≤25 s, >25 s, unable to complete. §Ejection fraction categories ≥50 (reference), 40–<50, 30–<40 and <30. ¶Heart rate categories: <50 (reference), 50–69, 70–79, 80–89, 90–99, 100–109, 110–129, 130–149 and ≥150 bpm. #Diastolic blood pressure categories: <50 (reference), 50–59, 60–69, 70–79, 80–89, 90–99 and ≥100. COPD, chronic obstructive pulmonary disease.

(initial heart rate, ischaemic ECG changes, initial haemoglobin, prior heart failure and length of stay), while others were common across both time periods (initial diastolic BP, ejection fraction, prior COPD, functional mobility and self-reported health status). In practice, our 30-day and 180-day readmission models may be used in conjunction to provide short-term and intermediate-term prognostication

Figure 2 Calibration of predicted versus observed probability of readmission at 180-days in the SILVER-AMI validation cohort, by quintile. Model calibration, validation cohort (by quintile). Shown are observed versus predicted 180-day readmission rates, by quintile, within the validation cohort. Error bars (red) represent 95% CIs. Among these quintiles, the SILVER-AMI readmission risk model was well calibrated (Hosmer-Lemeshow $p > 0.05$). SILVER-AMI, Comprehensive Evaluation of Risk in Older Adults with AMI.

for patients, family members, clinicians and health systems. While 30-day readmission risk may be more relevant for immediate care planning, 180-day risk is more relevant for ongoing outpatient management. Notably, functional mobility and health status served as robust indicators that were relevant across both time periods of risk, which argues for their measurement in the routine care of older adults. Prior studies in other AMI cohorts have found that both mobility and health status measures predict outcomes ranging from cardiovascular events²⁸ to hospital readmission²⁹ and survival,²⁹ although their measurement remains largely outside routine clinical practice.

Our initial pool of variables included those found in prior AMI readmission risk models, major functional impairments plausibly related to readmission and other variables based on clinical judgement that may potentially have influenced readmission. Despite this thorough selection process, as well as the broad range of care environments in SILVER-AMI, our model had only modest discrimination. We reported similar findings in our 30-day readmission model,⁶ which we believe underscores that other factors, such as those relating to the community or health system, may be important elements of readmission risk. In addition, while we captured in-hospital complications, our dataset did not include other events in the hospital (eg, delirium, inadequate nutrition and prolonged immobility) that are more difficult to quantify but may also contribute to readmission risk.^{3 4 30} Notably, a recent study by Rawal *et al*³⁰ of 207 medical inpatients found that those reporting disturbances in multiple domains of sleep, mobility, nutrition and mood were significantly more likely to be readmitted within 30 days than those reporting little or no disturbance, even after adjustment for age, sex, comorbidity burden, laboratory abnormalities and length of stay. To our knowledge, similar data have not been published for 180-day readmission, and further study is therefore needed to evaluate whether the hospital environment affects outcomes within this timeframe.

Mechanistically, we believe there are plausible explanations for the factors we found to be associated with readmission. For example, history of heart failure was the strongest independent predictor of 180-day readmission, and multiple studies have demonstrated that older adults with heart failure are prone to hospital readmissions both for cardiac-specific issues (eg, haemodynamic decompensation) and an array of non-cardiac causes.^{1 31} Impaired functional mobility was another independent predictor of 180-day readmission in our model and is a composite measure that encompasses balance and gait manoeuvres used on a daily basis; it has considerable overlap with the frailty syndrome.³² Participants with impaired functional mobility may have been at risk from both the stresses of inpatient hospitalisation as well as impaired recovery after discharge, placing them at heightened risk for readmission.

There are several limitations to our study that warrant consideration. First, while SILVER-AMI made an effort

to be broadly inclusive of hospitalised older adults, the recruitment process excluded those with severe cognitive impairment or delirium at presentation with no proxy available, given the requirement for completion of detailed study instruments. Therefore, while severe cognitive impairment may be an independent determinant of readmission in older adults,³³ it was not well represented in our dataset. Second, our risk model was based on first readmission and did not take multiple readmissions into account. Time to first event is the convention for most readmission risk models to avoid disproportionately weighing individuals with frequent readmissions. Third, while our model was internally validated, the model may perform differently in external datasets. To our knowledge, no such dataset for validation yet exists, but this remains a worthy exercise for future investigations.

In conclusion, among patients age ≥ 75 years hospitalised for AMI, we developed and internally validated a risk model for 180-day hospital readmission that considered a broad range of functional impairments, comorbidities and presentation characteristics. Two variables (impaired functional mobility and poor self-reported health status) not captured in most prior cohort studies were retained in the final risk model, along with more traditional clinical characteristics. Collection of functional mobility and health status can help to better determine postdischarge risk. However, while our model was well calibrated, it had only modest discrimination, suggesting that 180-day readmissions are also influenced by other factors: either related to the physiological stresses of hospitalisation (eg, sleep disruption) or community-level or health system-level factors (eg, timely access to outpatient care) that influence postdischarge outcomes.

Author affiliations

¹Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York, USA

²Division of Healthcare Delivery Science, Department of Population Health, New York University School of Medicine, New York, New York, USA

³Geriatrics Section, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA

⁴Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut, USA

⁵Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University, New Haven, Connecticut, USA

⁶Robert Wood Johnson Foundation Clinical Scholars Program, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA

⁷Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, USA

⁸Duke Clinical Research Institute, Durham, North Carolina, USA

⁹International Heart Institute of Montana, Missoula, Montana, USA

¹⁰Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA

Contributors JD: planning, article writing and submission; AH: planning, statistical check and article writing; TM: statistical analysis and article writing; MG: conducting, patient enrolment, data collection and reporting; HK: planning and article check; ST: data collection and reporting, and data check; MN and GO: article check; MT: planning and article check; DS: patient enrolment and article check; TMG: planning and article writing; SIC: principal investigator, planning, conducting and article writing.

Funding This research was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health (R01HL115295). This work was conducted

at the Yale Program on Aging/Claude D. Pepper Older Americans Independence Center (P30AG21342). The project described used REDCap, which is supported by the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through grant UL1 TR000000. JD is supported by a Patient Oriented Career Development Award (K23 AG052463) from the National Institute of Aging. AH was supported by NIA training grant T32 AG019134. TMG is the recipient of an Academic Leadership Award (K07AG043587) from the National Institute on Aging. MN is supported by an NIH training grant T32HL069749-15.

Disclaimer The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Competing interests SIC receives funding for her work as a reviewer for the CVS Caremark Clinical Pharmacy Program for the state of Connecticut.

Patient consent for publication Not required.

Ethics approval All Comprehensive Evaluation of Risk in Older Adults with AMI enrolment sites obtained support from their local Institutional Review Boards.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. Interested researchers can contact the senior author (SIC) for further information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

Correction notice This article has been corrected since it first published. The provenance and peer review statement has been included.

ORCID iD

John A Dodson <http://orcid.org/0000-0003-0163-3013>

REFERENCES

- 1 Dharmarajan K, Hsieh AF, Lin Z, *et al.* Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. *JAMA* 2013;309:355–63.
- 2 Blunt I, Bardsley M, Grove A, *et al.* Classifying emergency 30-day readmissions in England using routine hospital data 2004–2010: what is the scope for reduction? *Emerg Med J* 2015;32:44–50.
- 3 Krumholz HM. Post-hospital syndrome—an acquired, transient condition of generalized risk. *N Engl J Med* 2013;368:100–2.
- 4 Dharmarajan K, Hsieh AF, Kulkarni VT, *et al.* Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study. *BMJ* 2015;350:h411.
- 5 Dharmarajan K, Hsieh A, Dreyer RP, *et al.* Relationship between age and trajectories of rehospitalization risk in older adults. *J Am Geriatr Soc* 2017;65:421–6.
- 6 Dodson JA, Hajduk AM, Murphy TE, *et al.* Thirty-day readmission risk model for older adults hospitalized with acute myocardial infarction. *Circ Cardiovasc Qual Outcomes* 2019;12:e005320.
- 7 Greysen SR, Stijacic Cenzer I, Auerbach AD, *et al.* Functional impairment and hospital readmission in Medicare seniors. *JAMA Intern Med* 2015;175:559–65.
- 8 Dodson JA, Geda M, Krumholz HM, *et al.* Design and rationale of the comprehensive evaluation of risk factors in older patients with AMI (SILVER-AMI) study. *BMJ Health Serv Res* 2014;14:506.
- 9 Thygesen K, Alpert JS, Jaffe AS, *et al.* Third universal definition of myocardial infarction. *Eur Heart J* 2012;33:2551–67.
- 10 Dharmarajan K, Krumholz HM. Strategies to reduce 30-day readmissions in older patients hospitalized with heart failure and acute myocardial infarction. *Curr Geriatr Rep* 2014;3:306–15.
- 11 Krumholz HM, Lin Z, Drye EE, *et al.* An administrative claims measure suitable for profiling Hospital performance based on 30-day all-cause readmission rates among patients with acute myocardial infarction. *Circ Cardiovasc Qual Outcomes* 2011;4:243–52.
- 12 Desai MM, Stauffer BD, Feringa HHH, *et al.* Statistical models and patient predictors of readmission for acute myocardial infarction: a systematic review. *Circ Cardiovasc Qual Outcomes* 2009;2:500–7.
- 13 Burke RE, Schnipper JL, Williams MV, *et al.* The HOSPITAL score predicts potentially preventable 30-day readmissions in conditions targeted by the hospital readmissions reduction program. *Med Care* 2017;55:285–90.
- 14 Brandt J, Spencer M, Folstein M. The telephone interview for cognitive status. *Neuropsychiatry Neuropsychol Behav Neurol* 1988;1:111–7.

- 15 Rodríguez-Aranda C, Martinussen M. Age-related differences in performance of phonemic verbal fluency measured by controlled oral word association task (COWAT): a meta-analytic study. *Dev Neuropsychol* 2006;30:697–717.
- 16 Mangione CM, Lee PP, Gutierrez PR, *et al.* Development of the 25-item National eye Institute visual function questionnaire. *Arch Ophthalmol* 2001;119:1050.
- 17 Hayman KJ, Kerse N, Dyal L, *et al.* Life and living in advanced age: a cohort study in New Zealand--e Puāwaitanga o Nga Tapuwae Kia Ora Tonu, LiLACS NZ: study protocol. *BMC Geriatr* 2012;12:33.
- 18 Katz S. Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. *J Am Geriatr Soc* 1983;31:721–7.
- 19 Kroenke K, Strine TW, Spitzer RL, *et al.* The PHQ-8 as a measure of current depression in the general population. *J Affect Disord* 2009;114:163–73.
- 20 Rantanen T, Guralnik JM, Foley D, *et al.* Midlife hand grip strength as a predictor of old age disability. *JAMA* 1999;281:558–60.
- 21 Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. *J Am Geriatr Soc* 1991;39:142–8.
- 22 White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. *Stat Med* 2011;30:377–99.
- 23 Murphy TE, Tsang SW, Leo-Summers LS, *et al.* Bayesian model averaging for selection of a risk prediction model for death within thirty days of discharge: the SILVER-AMI study. *Int J Stat Med Res* 2019;8:1–7.
- 24 Rubin DB. *Multiple imputation for nonresponse in surveys* Donald B, 2004.
- 25 Sica GT. Bias in research studies. *Radiology* 2006;238:780–9.
- 26 Murphy TE, Gill TM, Leo-Summers LS, *et al.* The competing risk of death in longitudinal geriatric outcomes. *J Am Geriatr Soc* 2019;67:357–62.
- 27 Goldwater DS, Dharmarajan K, McEwan BS, *et al.* Is posthospital syndrome a result of hospitalization-induced allostatic overload? *J Hosp Med* 2018;13. doi:10.12788/jhm.2986. [Epub ahead of print: 30 May 2018].
- 28 Matsuzawa Y, Konishi M, Akiyama E, *et al.* Association between gait speed as a measure of frailty and risk of cardiovascular events after myocardial infarction. *J Am Coll Cardiol* 2013;61:1964–72.
- 29 Soto GE, Jones P, Weintraub WS, *et al.* Prognostic value of health status in patients with heart failure after acute myocardial infarction. *Circulation* 2004;110:546–51.
- 30 Rawal S, Kwan JL, Razak F, *et al.* Association of the trauma of hospitalization with 30-day readmission or emergency department visit. *JAMA Intern Med* 2019;179:38–45.
- 31 Feltner C, Jones CD, Cené CW, *et al.* Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis. *Ann Intern Med* 2014;160:774.
- 32 Milte R, Crotty M. Musculoskeletal health, frailty and functional decline. *Best Pract Res Clin Rheumatol* 2014;28:395–410. doi:10.1016/j.berh.2014.07.005
- 33 Daiello LA, Gardner R, Epstein-Lubow G, *et al.* Association of dementia with early rehospitalization among Medicare beneficiaries. *Arch Gerontol Geriatr* 2014;59:162–8.

Correction: 180-day readmission risk model for older adults with acute myocardial infarction: the SILVER-AMI study

Dodson JA, Hajduk AM, Murphy TE, *et al*. 180-day readmission risk model for older adults with acute myocardial infarction: the SILVER-AMI study. *Open Heart* 2021;8:e001442. doi:10.1136/openhrt-2020-001442

This article has been corrected since it was first published. The provenance and peer review statement has been included.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Open Heart 2021;8:e001442corr1. doi:10.1136/openhrt-2020-001442corr1